Skip to main content
Delta-Fly Pharma, Inc. logo

Delta-Fly Pharma, Inc. — Investor Relations & Filings

Ticker · 4598 ISIN · JP3549370009 T Professional, scientific and technical activities
Open in API
Filings indexed 63 across all filing types
Latest filing 2023-08-14 Report Publication Anno…
Country JP Japan
Listing T 4598

About Delta-Fly Pharma, Inc.

https://www.delta-flypharma.co.jp/en/

Delta-Fly Pharma, Inc. is a biopharmaceutical company specializing in the research and development of anticancer drugs. The company's core strategy is its proprietary "Module Drug Development" concept, an approach that combines existing pharmaceutical components to create novel therapeutic agents. This methodology aims to develop effective cancer treatments with significantly reduced side effects and at reasonable prices, thereby improving the quality of life for patients. The company's pipeline includes several drug candidates for various cancers, with some, such as DFP-10917 for refractory/relapsed acute myeloid leukemia, advancing to late-stage clinical trials. Delta-Fly Pharma focuses on creating gentle yet potent therapies, including nucleoside analogs and RNA therapeutics.

Recent filings

Filing Released Lang Actions
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakuninsho) filed under the Financial Instruments and Exchange Act of Japan, specifically confirming the accuracy of a Quarterly Report (Shihanki Hokokusho). Since this is a standalone regulatory filing confirming the validity of financial statements rather than the quarterly report itself, and it does not fit into the other specific categories like 10-K or IR, it is classified as a Regulatory Filing.
2023-08-14 Japanese
四半期報告書－第14期第1四半期(2023/04/01－2023/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a Japanese 'Quarterly Report' (四半期報告書) filed under the Financial Instruments and Exchange Act. It contains detailed financial statements, including the balance sheet and income statement for the first quarter of the 14th fiscal period (April 1, 2023, to June 30, 2023). Since it provides comprehensive financial data for an interim period rather than just an announcement or certification, it is classified as an Interim/Quarterly Report. Q1 2024
2023-08-14 Japanese
内部統制報告書－第13期(2022/04/01－2023/03/31)
Regulatory Filings
2023-06-26 Japanese
有価証券報告書－第13期(2022/04/01－2023/03/31)
Annual Report
2023-06-26 Japanese
確認書
Regulatory Filings
2023-06-26 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakuninsho) filed under the Financial Instruments and Exchange Act, specifically confirming the accuracy of the contents of a Quarterly Report (Shihanki Hokokusho) for the third quarter of the 13th fiscal period. Since this is a formal regulatory filing confirming the validity of financial statements rather than the financial report itself, and it does not fit into specific categories like 10-K or IR, it is classified as a Regulatory Filing.
2023-02-14 Japanese

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.